ATLANTA, July 10 /PRNewswire/ -- Purdue Pharma L.P. has reached a major milestone for the pharmaceutical manufacturing industry by successfully completing its first electronic transaction for a controlled substance. The transaction, completed by using the nuBridges e222 CSOS (Controlled Substance Ordering System) solution, is one of the first of its kind by a pharmaceutical manufacturer.
nuBridges e222 CSOS, which adheres to the Drug Enforcement Administration’s (DEA) strict security requirements for CSOS, manages all of the order and customer verification steps necessary in the electronic workflow. The solution was originally created by iSoft, acquired by nuBridges in May 2006.
The Drug Enforcement Administration’s CSOS regulation requires that the chain of custody must be verified and documented at every step in the transaction process. The e222 form, which allows companies to meet the standards but conduct business electronically, was first allowed by the DEA in 2005.
“This is a pivotal moment for Purdue and for controlled substance pharmaceutical manufacturing as a whole,” said Michael Celentano, Associate Director, Supply Chain Systems for Purdue. “With nuBridges e222 solution, we can reap the benefits of electronic CSOS compliance, knowing that our processes are secure, scalable and extremely efficient.”
Purdue and its wholesale customers, Value Drug and H. D. Smith, installed the nuBridges e222 solution, facilitating secure communication among all parties, streamlining order processing and ultimately improving customer service.
Secure, Efficient and Cost-Effective
A study by the DEA found that pharmaceutical companies and distributors can gain significant efficiencies and reduce costs with electronic processing over more traditional paper-bound models. According to the report, processing a single order via paper can cost up to $60, while electronic processing averages $6 and can be completed in real-time.
Prior to the expansion of CSOS to include electronic processing, buyers were severely constrained by a 10 line-item limit for each paper-based order. Orders in excess of 10 lines required the processing of multiple forms. Now, with e222, companies can order all Schedule I & II controlled substances purchases on a single electronic form. Partners can now meet critical supply needs, optimize ordering across the network and improve inventory management.
nuBridges’ e222 CSOS application is one of the industry’s first to be certified according to strict DEA requirements. The software is designed to provide the highest levels of integrity at every step in the process:
- Message encryption ensures that only authorized recipients can access content - Digital signatures assure identity, including return receipts - Audit trails account for all stock received, distributed or disposed of - Highly scalable, secure communications engine
“Pharmaceutical companies have great responsibilities: preventing the diversion of legitimate pharmaceutical drugs into illegal channels and ensuring sufficient supply for legitimate medical use,” said Bob Geiger, VP of Enterprise Solutions at nuBridges. “Purdue is raising the standard on this mandate -- embracing technology that makes it much easier for them to achieve both objectives.”
About nuBridges
nuBridges is the new way to do eBusiness: practical, pervasive and profitable. Our products and services provide one foundation for information exchange within your company and among your business partners. The industry pioneers and visionaries of the nuBridges’ team bring an expansive depth and breadth of experience to help companies do more with less in adaptive eBusiness environments. Providing affordable, agile and seamless electronic business solutions is our commitment to customers-exceeding their expectations is our goal. For more information, visit http://www.nubridges.com.
nuBridges, LLC
CONTACT: Company, Nate McNabb of nuBridges, LLC, +1-770-730-3792, ornmcnabb@nubridges.com; or Media, Mary Clancy of Corporate Ink,+1-617-969-9192, or mclancy@corporateink.com
Web site: http://www.nubridges.com//
